Medical imaging company United Imaging Healthcare (UIH) said on Wednesday that the US Food and Drug Administration (FDA) has cleared its next generation imaging platform, uPMR 790 HD TOF PET/MR.
The company stated that uPMR 790 redefines clinical routine imaging for PET/MR with the capability to scan a whole body within 20 minutes, balancing patient comfort with high-quality imaging. The next generation uPMR 790 delivers state-of-the-art PET and MR performance that is above the current technology standards.
According to the company, the HD TOF PET platform is based on digital silicon photomultipliers (SiPMs) and lutetium-yttrium oxyorthosilicate (LYSO) crystals, offering a 2.8 mm NEMA PET spatial resolution with time-of-flight (TOF) technology and a large 32cm axial field-of-view.
This new technology combined with compressed sensing for whole body isotropic 3D MR imaging results in fast simultaneous whole-body PET and MR scans as well as offering clinicians high isotropic spatial resolution to visualize small lesions while accelerating acquisition times to maximize patient comfort.
In addition, uPMR 790 offers cutting-edge imaging for research, including theranostics and neuroscience which benefit from an increase in sensitivity, resolution and coverage. UIH's uSync Research platform enables further opportunities for research in areas such as simultaneous tracking of PET and MRI tracers, real-time cardiac PET/MR, functional neurological PET/MR, and multi-parametric radiometrics.
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal